ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The Company’s major business is research and development and operates only in one single segment.
相关临床试验
23
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
13.0%
已完成
16
69.6%
招募中
2
8.7%
终止
1
4.3%
撤回
1
4.3%
暂无批准数据
暂无资讯文章
